H56:IC31结核疫苗候选物在成功治疗药物敏感性肺结核成人中的安全性和免疫原性:一项1期随机试验
这项1期随机试验将22名完成4-5个月抗结核治疗且确认结核分枝杆菌阴性的成人随机分组,间隔56天接受2剂H56:IC31(5 mg H56:500 nmol IC31;n=16)或安慰剂(n=6),随访420天。H56:IC31安全性可接受,主要为轻度自限性注射部位反应,未报告严重不良事件或疫苗相关严重不良事件;疫苗诱导以ESAT-6为免疫优势抗原的Ag85B和ESAT-6 CD4+ T细胞反应,持续至末次接种后6个月,并有一些Ag85B和ESAT-6 CD8+ T细胞反应的证据,但程度低于CD4+反应。
要点
- H56:IC31在近期治疗药物敏感性肺结核成人中安全性可接受,未报告严重不良事件。
- 疫苗诱导Ag85B和ESAT-6的CD4+ T细胞反应,ESAT-6为免疫优势抗原。
- CD4+ T细胞反应持续至末次接种后6个月,CD8+反应证据较弱。
核心结论
- H56:IC31在近期治疗药物敏感性、无并发症肺结核的成人中安全性可接受,并诱导以CD4+ T细胞为主的反应。
研究设计与样本
- 1期随机试验,22名完成4-5个月抗结核治疗且经2次GeneXpert检测或2次痰培养确认结核分枝杆菌阴性的成人,随机接受2剂H56:IC31(5 mg H56:500 nmol IC31;n=16)或安慰剂(n=6),间隔56天,随访420天。
主要发现
- H56:IC31接种与可接受的安全性特征相关,主要为轻度自限性注射部位反应。
- 未报告严重不良事件或疫苗相关严重不良事件。
- H56:IC31诱导Ag85B和ESAT-6的CD4+ T细胞反应,ESAT-6为免疫优势抗原,持续至末次接种后6个月。
- 有一些Ag85B和ESAT-6的CD8+ T细胞反应证据,但程度低于CD4+反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB. METHODS: Twenty-two adults confirmed to be Mycobacterium tuberculosis negative (by 2 GeneXpert tests or 2 sputum cultures) after 4-5 months of TB treatment, and not more than 28 days after completion of TB treatment, were randomized to receive 2 doses of H56:IC31 (5 mg H56:500 nmol IC31; n = 16) or placebo (n = 6) 56 days apart. Participants were followed for 420 days for safety and immunogenicity. RESULTS: H56:IC31 vaccination was associated with an acceptable safety profile, consisting mostly of mild self-limited injection site reactions. No serious adverse events or vaccine-related severe adverse events were reported. H56:IC31 induced a CD4+ T-cell response for Ag85B and ESAT-6, with ESAT-6 being immunodominant, which persisted through 6 months after the last vaccination. There was some evidence of CD8+ T-cell responses for both Ag85B and ESAT-6, but to a lesser extent than CD4+ responses. CONCLUSIONS: H56:IC31 was associated with an acceptable safety profile, and induced a predominant CD4+ T-cell response, in adults recently treated for drug-susceptible, uncomplicated pulmonary TB. CLINICAL TRIALS REGISTRATION: NCT02375698.
引用
- Tait D, Diacon A, Borges ÁH, et al. Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. J Infect Dis. 2024. PMID: 38557639. doi:10.1093/infdis/jiae170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。